Good Ventures awarded a grant of $300,000 to Yale University to support research on antibodies that change the permeability of the blood-brain barrier. If effective, the antibodies could enable new approaches toward treating Alzheimer’s disease, strokes, and other neurological disorders. This funding is intended to support work to identify the most effective antibodies, conduct affinity maturation of antibodies, and administer initial efficacy tests.
Good Ventures, with support from Open Philanthropy, has been investigating how best to fund scientific research that might help reduce the future burden of Alzheimer’s disease.